Jin, Y., Sun, W., Gu, D., Yang, J., Xu, Z., & Chen, J. (2012). Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: A meta-analysis. European Journal of Cancer Care, 22, 41–50.
To compare the therapeutic efficacy and safety of a single-dose of 0.25 mg or 0.75 mg palonosetron with first generation 5-HT3 RAs (32 mg ondansetron, 100 mg dolasetron, or 3 mg granisetron) in preventing chemotherapy-induced nausea and vomiting (CINV) with or without IV dexamethasone before initiation of chemotherapy
Databases searched were Medline (1966 to June 2011), EMBASE (1980 to June 2011), American Society of Clinical Oncology, and National Cancer Institute (403 in total).
Search keywords were palonosetron, ondansetron, granisetron, dolasetron, nausea and vomiting.
Studies were included in the review if they were
Studies were excluded if they had insufficient data on polanestron safety or if the participants were applied more than once in the review.
Results from the analysis suggest that palonosetron is highly effective in preventing nausea and vomiting in the days after administration of moderately or highly emetogenic chemotherapy agents.